Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib

Massimo Iavarone, Giuseppe Cabibbo, Marco Biolato, Cristina Della Corte, Marcello Maida, Marco Barbara, Michele Basso, Sara Vavassori, Antonio Craxì, Antonio Grieco, Carlo Cammà, Massimo Colombo

Research output: Contribution to journalArticle

Abstract

Treatment with sorafenib of patients with advanced hepatocellular carcinoma is challenged by anticipated discontinuation due to tumor progression, liver decompensation, or adverse effects. While postprogression survival is clearly determined by the pattern of tumor progression, understanding the factors that drive prognosis in patients who discontinued sorafenib for any reason may help to improve patient management and second-line trial design. Patients consecutively admitted to three referral centers who were receiving best supportive care following permanent discontinuation of sorafenib for any reason were included. Postsorafenib survival (PSS) was calculated from the last day of treatment to death or last visit available. Two hundred and sixty patients were included in this prospective study, aged 67 years, 60% with hepatitis C, 51% Child-Pugh A, 83% performance status (PS) ≥1, 41% with macroscopic vascular invasion, and 38% with extrahepatic tumor spread. Overall, median PSS was 4.1 (3.3-4.9) months, resulting from 4.6 (3.3-5.7) months for 123 progressors, 7.3 (6.0-10.0) months in 77 with adverse effects, and 1.8 (1.6-2.4) months in 60 decompensated patients (P

Original languageEnglish
Pages (from-to)784-791
Number of pages8
JournalHepatology
Volume62
Issue number3
DOIs
Publication statusPublished - Sep 1 2015

ASJC Scopus subject areas

  • Hepatology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib'. Together they form a unique fingerprint.

  • Cite this

    Iavarone, M., Cabibbo, G., Biolato, M., Della Corte, C., Maida, M., Barbara, M., Basso, M., Vavassori, S., Craxì, A., Grieco, A., Cammà, C., & Colombo, M. (2015). Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. Hepatology, 62(3), 784-791. https://doi.org/10.1002/hep.27729